Author

Florian Rieder

Gazing into the Crystal Ball: Current and Future Perspectives for Crohn’s Disease Complications (Boehringer Ingelheim)
Gazing into the Crystal Ball: Current and Future Perspectives for Crohn’s Disease Complications (Boehringer Ingelheim)

Florian Rieder  et al.

Fibrosis and strictures - treatment at last?
Fibrosis and strictures - treatment at last?

Florian Rieder

European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease
European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease

Florian Rieder  et al.

Intestinal fibrosis in IBD
Intestinal fibrosis in IBD

Florian Rieder

TL1A BLOCKADE BY PRA023 LEADS TO REDUCTION OF INFLAMMATORY AND FIBROTIC PATHWAYS IN PATIENTS WITH CROHN’S DISEASE
TL1A BLOCKADE BY PRA023 LEADS TO REDUCTION OF INFLAMMATORY AND FIBROTIC PATHWAYS IN PATIENTS WITH CROHN’S DISEASE

Florian Rieder  et al.

IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES
IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES

Florian Rieder  et al.

EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY
EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY

Florian Rieder  et al.

TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS
TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

Florian Rieder  et al.

GROUP-BASED TRAJECTORY MODELING TO IDENTIFY RESPONSE PATTERNS TO OZANIMOD TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
GROUP-BASED TRAJECTORY MODELING TO IDENTIFY RESPONSE PATTERNS TO OZANIMOD TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Florian Rieder  et al.

EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS
EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Florian Rieder  et al.

EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES
EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES

Florian Rieder  et al.

RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES
RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES

Florian Rieder  et al.

PRA023, AN ANTI-TL1A INHIBITORY ANTIBODY, REDUCED INFLAMMATORY AND FIBROSIS ASSOCIATED BIOMARKERS IN ULCERATIVE COLITIS PATIENTS WHO ACHIEVED CLINICAL REMISSION
PRA023, AN ANTI-TL1A INHIBITORY ANTIBODY, REDUCED INFLAMMATORY AND FIBROSIS ASSOCIATED BIOMARKERS IN ULCERATIVE COLITIS PATIENTS WHO ACHIEVED CLINICAL REMISSION

Florian Rieder  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Florian Rieder  et al.

EXPERT CONSENSUS TO STANDARDISE TRANSCRIPTOME ANALYSIS IN INFLAMMATORY BOWEL DISEASE CLINICAL TRIALS
EXPERT CONSENSUS TO STANDARDISE TRANSCRIPTOME ANALYSIS IN INFLAMMATORY BOWEL DISEASE CLINICAL TRIALS

Florian Rieder  et al.

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects

Florian Rieder  et al.

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES
A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Florian Rieder  et al.

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

Florian Rieder  et al.

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

Florian Rieder  et al.

A GLOBAL CONSENSUS ON THE DEFINITIONS, DIAGNOSIS AND MANAGEMENT OF FIBROSTENOSING SMALL BOWEL CROHN'S DISEASE
A GLOBAL CONSENSUS ON THE DEFINITIONS, DIAGNOSIS AND MANAGEMENT OF FIBROSTENOSING SMALL BOWEL CROHN'S DISEASE

Florian Rieder  et al.

Item 1 - 20 / 20
1